image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 35.57
-1.69 %
$ 1.96 B
Market Cap
33.24
P/E
1. INTRINSIC VALUE

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.[ Read More ]

The intrinsic value of one SUPN stock under the base case scenario is HIDDEN Compared to the current market price of 35.6 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SUPN

image
FINANCIALS
608 M REVENUE
-8.95%
-5.27 M OPERATING INCOME
-7.83%
1.32 M NET INCOME
-97.83%
111 M OPERATING CASH FLOW
-4.91%
269 M INVESTING CASH FLOW
224.03%
-398 M FINANCING CASH FLOW
-3697.65%
176 M REVENUE
4.37%
40.8 M OPERATING INCOME
124.25%
38.5 M NET INCOME
93.30%
53.5 M OPERATING CASH FLOW
50.24%
-77 M INVESTING CASH FLOW
-58.48%
3.08 M FINANCING CASH FLOW
85.46%
Balance Sheet Decomposition Supernus Pharmaceuticals, Inc.
image
Current Assets 493 M
Cash & Short-Term Investments 255 M
Receivables 144 M
Other Current Assets 94.1 M
Non-Current Assets 785 M
Long-Term Investments 16.6 M
PP&E 42.5 M
Other Non-Current Assets 725 M
Current Liabilities 290 M
Accounts Payable 1.96 M
Short-Term Debt 8.33 M
Other Current Liabilities 280 M
Non-Current Liabilities 66 M
Long-Term Debt 33.2 M
Other Non-Current Liabilities 32.8 M
EFFICIENCY
Earnings Waterfall Supernus Pharmaceuticals, Inc.
image
Revenue 608 M
Cost Of Revenue 83.8 M
Gross Profit 524 M
Operating Expenses 529 M
Operating Income -5.27 M
Other Expenses -6.58 M
Net Income 1.32 M
RATIOS
86.21% GROSS MARGIN
86.21%
-0.87% OPERATING MARGIN
-0.87%
0.22% NET MARGIN
0.22%
0.14% ROE
0.14%
0.10% ROA
0.10%
-0.27% ROIC
-0.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Supernus Pharmaceuticals, Inc.
image
Net Income 1.32 M
Depreciation & Amortization 84.9 M
Capital Expenditures -551 K
Stock-Based Compensation 26.8 M
Change in Working Capital -9.14 M
Others 35.3 M
Free Cash Flow 111 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Supernus Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for SUPN of $38.8 , with forecasts ranging from a low of $36 to a high of $41 .
SUPN Lowest Price Target Wall Street Target
36 USD 1.21%
SUPN Average Price Target Wall Street Target
38.8 USD 8.94%
SUPN Highest Price Target Wall Street Target
41 USD 15.27%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Supernus Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
11.6 M USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
3.35 M USD 1
9-12 MONTHS
584 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 days ago
Nov 11, 2024
Sell 388 K USD
NEWHALL CHARLES W III
Director
- 10700
36.24 USD
1 week ago
Nov 08, 2024
Sell 316 K USD
Hudson Frederick M.
Director
- 8722
36.28 USD
1 week ago
Nov 08, 2024
Sell 392 K USD
GEMAYEL GEORGES
Director
- 10787
36.3 USD
1 week ago
Nov 08, 2024
Sell 4.54 M USD
Khattar Jack A.
President, CEO
- 125000
36.29 USD
1 week ago
Nov 07, 2024
Sell 555 K USD
Mottola Frank
SVP, Quality, GMP, Ops, IT
- 15000
36.98 USD
1 week ago
Nov 07, 2024
Sell 520 K USD
GEMAYEL GEORGES
Director
- 14213
36.62 USD
1 week ago
Nov 07, 2024
Sell 4.58 M USD
Khattar Jack A.
President, CEO
- 125000
36.68 USD
2 months ago
Sep 13, 2024
Sell 313 K USD
GEMAYEL GEORGES
Director
- 10000
31.33 USD
7 months ago
Mar 21, 2024
Sell 512 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 14491
35.31 USD
7 months ago
Mar 20, 2024
Sell 14.1 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 400
35.31 USD
7 months ago
Mar 19, 2024
Sell 437 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 12364
35.31 USD
8 months ago
Mar 13, 2024
Sell 895 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 26250
34.1 USD
8 months ago
Mar 13, 2024
Sell 1.21 M USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 36116
33.48 USD
8 months ago
Mar 12, 2024
Sell 128 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 3884
32.99 USD
8 months ago
Feb 26, 2024
Sell 151 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 5000
30.21 USD
10 months ago
Jan 10, 2024
Sell 223 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 8000
27.91 USD
1 year ago
Nov 16, 2023
Sell 70 K USD
NEWHALL CHARLES W III
Director
- 2500
28.01 USD
1 year ago
Nov 15, 2023
Sell 111 K USD
Hudson Frederick M.
Director
- 3882
28.5 USD
1 year ago
Nov 15, 2023
Sell 149 K USD
Hudson Frederick M.
Director
- 5211
28.5 USD
1 year ago
Nov 14, 2023
Sell 31.2 K USD
Mottola Frank
SVP, Quality, GMP, Ops, IT
- 1110
28.13 USD
1 year ago
Aug 30, 2023
Sell 259 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 8100
32 USD
1 year ago
Aug 25, 2023
Sell 162 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 5135
31.59 USD
1 year ago
Mar 14, 2023
Sell 172 K USD
Mottola Frank
Sr VP, Quality, GMP Oper. & IT
- 4780
35.988 USD
1 year ago
Feb 03, 2023
Sell 8.4 K USD
Khattar Jack A.
President, CEO
- 200
42.02 USD
1 year ago
Feb 02, 2023
Sell 569 K USD
Khattar Jack A.
President, CEO
- 13532
42.055 USD
1 year ago
Feb 01, 2023
Sell 12.6 K USD
Khattar Jack A.
President, CEO
- 300
42.0067 USD
1 year ago
Jan 31, 2023
Sell 41 K USD
Khattar Jack A.
President, CEO
- 976
42.0106 USD
1 year ago
Jan 18, 2023
Sell 199 K USD
Khattar Jack A.
President, CEO
- 4936
40.3959 USD
1 year ago
Jan 17, 2023
Sell 193 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 4826
39.9167 USD
1 year ago
Jan 17, 2023
Sell 1.02 M USD
Khattar Jack A.
President, CEO
- 25446
40.0349 USD
1 year ago
Jan 06, 2023
Sell 6.94 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 174
39.9 USD
1 year ago
Dec 21, 2022
Sell 433 K USD
Khattar Jack A.
President, CEO
- 11354
38.1425 USD
1 year ago
Dec 20, 2022
Sell 152 K USD
Khattar Jack A.
President, CEO
- 4006
38.0222 USD
1 year ago
Dec 01, 2022
Sell 187 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 5000
37.4832 USD
1 year ago
Nov 25, 2022
Sell 392 K USD
Khattar Jack A.
President, CEO
- 11135
35.176 USD
1 year ago
Nov 23, 2022
Sell 79.2 K USD
Khattar Jack A.
President, CEO
- 2259
35.0548 USD
1 year ago
Nov 22, 2022
Sell 21 K USD
Khattar Jack A.
President, CEO
- 600
35.0018 USD
1 year ago
Nov 21, 2022
Sell 18.6 K USD
Khattar Jack A.
President, CEO
- 531
35.0136 USD
2 years ago
Nov 15, 2022
Sell 39 K USD
Khattar Jack A.
President, CEO
- 1115
35.0027 USD
2 years ago
Nov 11, 2022
Sell 238 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 6800
34.9493 USD
2 years ago
Nov 09, 2022
Sell 24.5 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 700
34.9713 USD
2 years ago
Aug 22, 2022
Sell 180 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 5000
35.98 USD
2 years ago
Aug 16, 2022
Sell 500 K USD
Khattar Jack A.
President, CEO
- 14690
34.013 USD
2 years ago
Aug 15, 2022
Sell 589 K USD
Khattar Jack A.
President, CEO
- 17302
34.028 USD
2 years ago
Aug 10, 2022
Sell 888 K USD
Khattar Jack A.
President, CEO
- 28437
31.22 USD
2 years ago
Aug 09, 2022
Sell 1.23 M USD
Khattar Jack A.
President, CEO
- 39431
31.15 USD
2 years ago
Aug 08, 2022
Sell 3.39 M USD
Khattar Jack A.
President, CEO
- 107875
31.4 USD
2 years ago
Aug 08, 2022
Sell 322 K USD
Khattar Jack A.
President, CEO
- 10032
32.11 USD
2 years ago
Aug 04, 2022
Sell 165 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 5000
32.98 USD
3 years ago
Apr 13, 2021
Sell 93.7 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 3125
29.9846 USD
3 years ago
Apr 14, 2021
Sell 99.9 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 3125
31.98 USD
3 years ago
Dec 21, 2020
Sell 1.02 M USD
Schwabe Stefan K.F.
Executive Vice President & CMO
- 46347
22.1042 USD
3 years ago
Dec 14, 2020
Sell 1.09 M USD
Schwabe Stefan K.F.
Executive Vice President & CMO
- 50000
21.8579 USD
3 years ago
Dec 14, 2020
Sell 80.4 K USD
Schwabe Stefan K.F.
Executive Vice President & CMO
- 3653
22.0007 USD
4 years ago
Nov 09, 2020
Sell 125 K USD
PATRICK GREGORY S
Sr. VP Chief Financial Officer
- 5000
25 USD
4 years ago
Nov 05, 2020
Sell 115 K USD
PATRICK GREGORY S
Sr. VP, CFO
- 5000
23 USD
4 years ago
Oct 15, 2020
Sell 301 K USD
PATRICK GREGORY S
Sr. VP, CFO
- 15000
20.0338 USD
4 years ago
Jul 13, 2020
Sell 22.5 K USD
Hudson Frederick M.
Director
- 920
24.44 USD
4 years ago
May 20, 2020
Sell 375 K USD
PATRICK GREGORY S
Sr.VP, Chief Financial Officer
- 15000
25.0253 USD
4 years ago
May 08, 2020
Sell 347 K USD
PATRICK GREGORY S
Sr VP, Chief Financial Officer
- 15000
23.1356 USD
5 years ago
Aug 23, 2019
Bought 190 K USD
Khattar Jack A.
President, CEO
+ 7200
26.3864 USD
5 years ago
Feb 27, 2019
Sell 831 K USD
PATRICK GREGORY S
Sr VP, Chief Financial Officer
- 20000
41.5325 USD
6 years ago
Jul 02, 2018
Sell 1.98 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 35000
56.6261 USD
6 years ago
Jun 28, 2018
Sell 204 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 3402
59.9351 USD
6 years ago
Jun 29, 2018
Sell 263 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 4393
59.9028 USD
6 years ago
Jun 21, 2018
Sell 432 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 7205
60.0032 USD
6 years ago
Jun 18, 2018
Sell 3.26 M USD
Schwabe Stefan K.F.
Executive VP R&D, CMO
- 60000
54.3892 USD
6 years ago
May 15, 2018
Sell 434 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 7500
57.9256 USD
6 years ago
May 10, 2018
Sell 998 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
49.8772 USD
6 years ago
May 11, 2018
Sell 1.04 M USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
52.0279 USD
6 years ago
May 11, 2018
Sell 630 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 10882
57.9 USD
6 years ago
May 11, 2018
Sell 898 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 16250
55.2334 USD
6 years ago
Apr 18, 2018
Sell 471 K USD
Vaughn Victor
Sr. VP of Sales & Marketing
- 10000
47.0617 USD
6 years ago
Apr 19, 2018
Sell 385 K USD
Vaughn Victor
Sr. VP of Sales & Marketing
- 7850
49.0261 USD
6 years ago
Apr 05, 2018
Sell 850 K USD
Vaughn Victor
Sr. VP of Sales and Marketing
- 18750
45.3295 USD
6 years ago
Jan 22, 2018
Sell 961 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
48.0358 USD
6 years ago
Jan 17, 2018
Sell 416 K USD
Vaughn Victor
Sr. VP of Sales
- 9250
45 USD
6 years ago
Jan 17, 2018
Sell 705 K USD
Vaughn Victor
Sr. VP of Sales
- 15000
47.0333 USD
6 years ago
Jan 17, 2018
Sell 900 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
44.975 USD
6 years ago
Jan 12, 2018
Sell 259 K USD
Vaughn Victor
Sr. VP of Sales
- 5750
45.0309 USD
6 years ago
Jan 11, 2018
Sell 2.18 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 50000
43.5629 USD
6 years ago
Jan 09, 2018
Sell 631 K USD
Vaughn Victor
Sr. VP of Sales
- 15000
42.0433 USD
6 years ago
Jan 02, 2018
Sell 2.21 M USD
Vaughn Victor
Sr. VP of Sales
- 55000
40.1147 USD
7. News
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdom. globenewswire.com - 3 days ago
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities. seekingalpha.com - 4 days ago
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com - 1 week ago
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to loss of $0.29 per share a year ago. zacks.com - 1 week ago
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder (MDD). globenewswire.com - 2 weeks ago
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024. globenewswire.com - 3 weeks ago
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md. globenewswire.com - 1 month ago
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder. globenewswire.com - 1 month ago
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her. globenewswire.com - 1 month ago
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate virtually in a fireside chat at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26, 2024, at 8:40 a.m. ET. globenewswire.com - 1 month ago
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable. seekingalpha.com - 2 months ago
8. Profile Summary

Supernus Pharmaceuticals, Inc. SUPN

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.96 B
Dividend Yield 0.00%
Description Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Contact 9715 Key West Avenue, Rockville, MD, 20850 https://www.supernus.com
IPO Date May 1, 2012
Employees 652
Officers Dr. Todd Horich M.B.A., Ph.D. Senior Vice President of Marketing, Commercial Operations & Market Access Mr. Jack A. Khattar M.B.A. Founder, President, Chief Executive Officer, Secretary & Director Mr. Frank Mottola Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs Dr. Jonathan Rubin M.B.A., M.D. Senior Vice President of Research & Development and Chief Medical Officer Mr. Kevin T. Anderson Esq. Compliance Officer Mr. Taylor Raiford Senior Vice President of Sales Dr. Bryan A. Roecklein Ph.D. Senior Vice President of Corporate Development Mr. Jeff Bozick Senior Vice President of Supply Chain Mr. Timothy C. Dec Senior Vice President & Chief Financial Officer Dr. Padmanabh P. Bhatt Ph.D. Chief Scientific Officer & Senior Vice President of Intellectual Property